Hepatotoxicity after high-dose intravenous methylprednisolone in multiple sclerosis patients.

Milagros Hidalgo de la CruzJahir Andrés Miranda AcuñaAlberto Lozano RosMaría Vega CatalinaEmilio Salinero PaniaguaGerardo Clemente RicoteClara Dionisia De Andrés FrutosMaría Luisa Martínez Ginés

Published in: Clinical case reports (2017)

Hepatotoxicity is a rare adverse event of methylprednisolone that should be considered in clinical practice. In patients at risk, we propose liver function surveillance, by measuring hepatic enzymes concentration 15-30 days after methylprednisolone administration. Additionally, we propose ACTH, dexamethasone, or plasma exchange as alternate treatment options for these patients.

Keyphrases

high dose
multiple sclerosis
end stage renal disease
newly diagnosed
ejection fraction
prognostic factors
public health
stem cell transplantation
patient reported outcomes
adverse drug